STOP Study: Incidence and Predictors of ALT Flares in HBeAg-Negative Patients Discontinuing NA Therapy for CHB

April 10-14, 2019; Vienna, Austria
Male sex and high HBV DNA were associated with increased flare risk in this single-center, randomized phase IV study.
Format: Microsoft PowerPoint (.ppt)
File Size: 175 KB
Released: April 15, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
AbbVie
Gilead Sciences

Related Content

Dr Graham Foster on optimizing management of HBV in older adults, from Clinical Care Options (CCO)

Graham R. Foster, FRCP, PhD Released: January 17, 2023

Expert analysis by Dr Nancy Reau on new viral hepatitis data from AASLD 2022, from Clinical Care Options (CCO)

Nancy Reau, MD Released: December 8, 2022

Clinical Care Options (CCO) expert analysis by Dr Stefan Zeuzem on new viral hepatitis data from AASLD 2022

Stefan Zeuzem, MD Released: December 7, 2022

Dr Nancy Reau: practice-changing viral hepatitis data from AASLD 2022, from Clinical Care Options (CCO)

Nancy Reau, MD Released: December 6, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings